论文部分内容阅读
目的 分析奥氮平联合利培酮治疗精神分裂症患者的临床效果.方法 选取2018年2月～2019年2月64例精神分裂症患者作为研究对象.运用随机数表法将其分为实验组与对照组,各32例.对照组患者采用利培酮治疗,实验组患者采用奥氮平联合利培酮治疗,对比两组患者治疗效果、身体指标、阳性与阴性症状量表(positive and negative syndrome scale,PANNS)指标及治疗满意度.结果 实验组患者治疗效果优于对照组(P ＜ 0.05).治疗前,两组患者身体指标、PANNS指标水平差异无统计学意义(P ＞ 0.05),治疗后,实验组身体指标改善程度优于对照组,PANNS指标、实验组患者阳性症状评分为(15.23±4.16)分,阴性症状评分为(13.57±2.63)分,均低于对照组患者的阳性症状和阴性症状评分(P ＜ 0.05),实验组患者治疗满意度为87.50％,高于对照组患者治疗满意度(81.25％),结果差异具有统计学意义(P ＜ 0.05).结论 精神分裂症患者实施奥氮平联合利培酮治疗,效果显著,改善了患者阳性、阴性症状,满足了患者治疗效果.“,”Objective To analyze the clinical effect of azepine combined with risperidone in the treatment of schizophrenia.Methods 64 patients with schizophrenia from February 2018 to February 2019 were selected and randomly divided into experimental group and control group with 32 cases in each group.The control group was treated with risperidone,and the experimental group was treated with azepine combined with risperidone.The treatment effect,body index,panns index and treatment satisfaction of the two groups were compared.Results The treatment effect of the experimental group was better than that of the control group (P＜0.05). Before treatment, there was no significant difference in body index and panns index between the two groups (P＞0.05). After treatment, the improvement degree of body index in the experimental group was better than that in the control group, and the score of body index and positive symptoms in the experimental group was (15.23±4.16), and the negative symptom score was (13.57±2.63) (P＜0.05) The treatment satisfaction of the experimental group was 87.50％, higher than that of the control group (81.25％), the difference was statistically significant (P＜0.05). Conclusion The treatment of schizophrenia patients with olanzapine combined with risperidone has a significant effect, which improves the patient\'\'s positive and negative symptoms and satisfies the patient\'\'s therapeutic effect.